Safety and efficacy of nemolizumab for atopic dermatitis up to 2&#x2009;years in open-label extension study

Atopic Dermatitis

Skin Clearance, Duration of Treatment-free Interval, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Open-label Extension Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis

J Am Acad Dermatol

Bissonnette R, Gold LS, Kircik L, Simpson EL, Eichenfield LF, Browning J, Hebert AA, Alexis AF, Soong W, Piscitelli SC, Tallman AM, Rubenstein DS, Brown PM, Silverberg JI

doi: 10.1016/j.jaad.2025.05.1391

Acne

Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension

J Am Acad Dermatol

Sayed CJ, Kirby B, Garg A, Naik HB, Kimball AB, Zouboulis CC, Jemec GBE, Kokolakis G, Ingram JR, Morita A, Deherder D, Crater C, Rolleri RL, Vaux T, Lambert J, Lukowski B, Bechara FG

doi: 10.1016/j.jaad.2025.11.031

Psoriatic Arthritis

Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis

Arthritis Res Ther

Gladman DD, Nash P, Mease PJ, FitzGerald O, Duench S, Cadatal MJ, Masri KR

doi: 10.1186/s13075-024-03442-2

Melanoma and Skin Cancer

Efficacy and safety of cosibelimab in advanced cutaneous squamous cell carcinoma: Results from a Pivotal Open-label Study with a median follow-up of ≥2 years

J Am Acad Dermatol

Ruiz ES, Muñoz-Couselo E, Montaudié H, Berciano-Guerrero MA, de la Gala MDCÁ, Charles J, Quéreux G, Nardin C, Tur RY, Dalle S, Beylot-Barry M, Ladwa R, McGrath M, Brungs D, Harris D, Shue H, Tazbirkova A, Fourie S, Malan DR, Oliviero J, Wilcoxen LN, Gray WG, Clingan P

doi: 10.1016/j.jaad.2025.09.009

Further Publications Rheumatology

Long-Term Safety and Efficacy of Bimekizumab in Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies

Rheumatology (Oxford)

Baraliakos X, Deodhar A, van der Heijde D, Van den Bosch F, Magrey M, Maksymowych WP, Tomita T, Xu H, Massow U, Vaux T, Prajapati C, Manente M, Marten A, Gensler LS

doi: 10.1093/rheumatology/keaf009

Atopic Dermatitis

Efficacy and safety of lebrikizumab in adult and adolescent patients with moderate-to-severe atopic dermatitis inadequately controlled with or ineligible for ciclosporin A: a placebo-controlled, randomized phase IIIb clinical study (ADvantage)

Br J Dermatol

Warren RB, de Bruin-Weller M, Tsianakas A, Khemis A, Szepietowski JC, Hong HC, Mihaylov Y, Falqués M, Agell H, Massana E, Gil EG, Coll R, Weidinger S

doi: 10.1093/bjd/ljaf285

Psoriasis

Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials

J Eur Acad Dermatol Venereol

Armstrong AW, Lebwohl M, Warren RB, Sofen H, Morita A, Paul C, Papp KA, Colombo MJ, Scotto J, Vaile J, Zhuo J, Vritzali E, Berger V, Schroeder G, Banerjee S, Thaçi D, Strober B

doi: 10.1111/jdv.20553

Atopic Dermatitis

Effectiveness and Safety of Tralokinumab in Atopic Dermatitis: 1-year Results From a Real-world Multicentre Study

Acta Derm Venereol

Calabrese L, Cinotti E, D'Onghia M, Cartocci A, Rubegni P, Maccari F, Boulard C, Reguiai Z, Becherel PA, Jacobzone C, Begon E, Fite C, Walls B, Liegeon AL, Parier J, Chaby G, Perrot JL, Omcci Group

doi: 10.2340/actadv.v105.42275

Atopic Dermatitis

Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6 years

J Eur Acad Dermatol Venereol

Bunick CG, Irvine AD, Silverberg JI, Guttman-Yassky E, Shahriari M, Gao X, Weidinger S, Katoh N, Vigna N, Dilley DM, D'Andrea E, Teixeira HD, Platt AM, Levy GF

doi: 10.1111/jdv.70172

Dermatology · Immunology · Rheumatology

Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open-label extension study

Related content

Skin Clearance, Duration of Treatment-free Interval, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Open-label Extension Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis

Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension

Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis

Efficacy and safety of cosibelimab in advanced cutaneous squamous cell carcinoma: Results from a Pivotal Open-label Study with a median follow-up of ≥2 years

Long-Term Safety and Efficacy of Bimekizumab in Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies

Efficacy and safety of lebrikizumab in adult and adolescent patients with moderate-to-severe atopic dermatitis inadequately controlled with or ineligible for ciclosporin A: a placebo-controlled, randomized phase IIIb clinical study (ADvantage)

Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials

Effectiveness and Safety of Tralokinumab in Atopic Dermatitis: 1-year Results From a Real-world Multicentre Study

Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6 years